ProQR Therapeutics N.V. Research And Development Expense

• ProQR Therapeutics N.V. showed an increase of +23.0% in Research And Development Expense from 2024 to 2025.
• This data is from ProQR Therapeutics N.V.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), ProQR Therapeutics N.V.'s Research And Development Expense has grown by 91.2%.
• Historical annual values: Fiscal year 2025: $44.73 million | Fiscal year 2024: $36.36 million | Fiscal year 2023: $25.15 million | Fiscal year 2022: $50.87 million | Fiscal year 2021: $42.22 million | Fiscal year 2020: $38.14 million | Fiscal year 2019: $46.49 million | Fiscal year 2018: $29.51 million | Fiscal year 2017: $31.15 million | Fiscal year 2016: $31.92 million | Fiscal year 2015: $23.40 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026